Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure

Sunwen Chou, Gail Marousek, Terry L. Bowlin

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Human cytomegalovirus (CMV) UL54 DNA polymerase (pol) mutants with known patterns of resistance to current antivirals ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV) were tested for cyclopropavir (CPV) susceptibility by a standardized reporter-based yield reduction assay. Exonuclease and A987G (region V) mutations at codons commonly associated with dual GCV-CDV resistance in clinical isolates paradoxically conferred increased CPV susceptibility. Various polymerase catalytic region mutations conferring FOS resistance with variable low-grade GCV and CDV cross-resistance also conferred CPV resistance, with 50% effective concentration (EC 50) increases of 3- to 13-fold. CPV EC 50 values against several pol mutants were increased about 2-fold by adding UL97 mutation C592G. Propagation of a CMV exonuclease mutant under CPV selected for pol mutations less often than UL97 mutations. In 21 experiments, one instance each of mutations E756D and M844V, which were shown individually to confer 3- to 4-fold increases in CPV EC 50, was detected. Unlike GCV and CDV, exonuclease mutations are not a preferred mechanism of CPV resistance, but mutations in and near pol region III may confer CPV resistance by affecting its recognition as an incoming base for DNA polymerization.

Original languageEnglish (US)
Pages (from-to)197-201
Number of pages5
JournalAntimicrobial agents and chemotherapy
Issue number1
StatePublished - Jan 2012
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure'. Together they form a unique fingerprint.

Cite this